<DOC>
	<DOCNO>NCT01830660</DOCNO>
	<brief_summary>Hetrombopag Olamine make Jiangsu Hengrui Medicine co Ltd. show effect increase platelet count animal human . This study design dose escalation fashion evaluate safety , pharmacokinetics efficacy Hetrombopag Olamine .</brief_summary>
	<brief_title>A Phase I Study Hetrombopag Olamine Healthy Adult Volunteers</brief_title>
	<detailed_description>1 . To evaluate safety tolerability Hetrombopag Olamine . 2 . To investigate pharmacokinetics Hetrombopag Olamine Under fast condition . 3 . To obtain pharmacodynamics information Hetrombopag Olamine platelet count elevation healthy volunteer . 4 . To determine preliminary regimen phase II study .</detailed_description>
	<criteria>1 . Subject must adequately inform nature risk study , able understand risk associate study , willing provide write informed consent prior screen . 2 . Must healthy male age 18 45 year , inclusive . 3 . Must BMI 19 28 kg/m2 , inclusive total body weight â‰¥50 kg . 4 . Platelet count must within normal range . 5 . Subjects must free clinically significant disease base medical history physical examination . 6 . Clinical laboratory test ( complete blood count [ CBC ] , blood chemistry , urinalysis ) must within normal limit clinically acceptable . 7 . Must nonsmoker , define smoked tobacco use chew tobacco nicotine . 8 . Subjects reproductive potential partner woman childbearing potential , instructed , must willing practice highly effective method birth control duration study continue 6 month discontinue treatment investigational product . 1 . History hypersensitivity hetrombopag olamine component . 2 . History presence significant cardiovascular deficient , pulmonary , hepatic , gallbladder biliary tract , renal , hematological , gastrointestinal , endocrine , immunological , dermatological , neurological , psychiatric disease , condition know interfere absorption , distribution , metabolism , excretion drug . 3 . History deep vein thrombosis , thromboembolic event . 4 . History presence condition may place subject increase risk determine investigator . 5 . History thrombocytopenia bleed due abnormal platelet number function . 6 . History platelet clump prevents reliable measurement platelet count .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>